Streetbeat News

GNPX

Genprex, Inc.

https://www.genprex.com

Industry

Biotechnology

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Open

1.10

Mkt cap

9.7M

Volume

739K

High

1.20

P/E Ratio

-0.11

52-wk high

14.40

Low

1.08

Div yield

N/A

52-wk low

0.28

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals saw substantial gains, while Alto Neuroscience and Ensysce Biosciences faced notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:07 pm

Stride, Inc. (NYSE:LRN) shares surged over 24% in pre-market trading after reporting better-than-expected Q1 earnings and issuing strong FY25 revenue guidance. Other notable pre-market movers include CNS Pharmaceuticals, DBV Technologies, and Enphase Energy, among others.

Portfolio Pulse from Avi Kapoor

October 23, 2024 | 10:36 am

In Tuesday's after-market session, several healthcare stocks experienced significant price movements. Protagenic Therapeutics, Talphera, Context Therapeutics, Fortrea Holdings, Genelux, and ENDRA Life Sciences saw gains, while TELA Bio, Ensysce Biosciences, Genprex, Allakos, Sensei Biotherapeutics, and TuHURA Biosciences experienced declines.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 8:31 pm

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Ensysce Biosciences, ENDRA Life Sciences, and Genprex saw substantial gains, while IN8bio, GRI Bio, and Voyager Therapeutics faced notable declines.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 4:31 pm

U.S. stocks fell with the Dow Jones down over 150 points. General Motors (GM) reported strong Q3 results, beating earnings and sales expectations, and raised its 2024 EPS guidance. Several biotech stocks saw significant price movements, with Genprex and Ensysce Biosciences surging, while GRI Bio and others declined.

Portfolio Pulse from Avi Kapoor

October 22, 2024 | 2:03 pm

In Tuesday's pre-market session, several health care stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also declined following its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also saw a decrease following its Q3 earnings report.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

iRhythm Technologies shares surged over 20% in pre-market trading following FDA clearance for its Zio AT device. Other notable pre-market movers include Genprex, SRM Entertainment, and TC Biopharm, with significant gains, while companies like IN8bio and DMC Global saw declines.

Portfolio Pulse from Avi Kapoor

October 22, 2024 | 11:06 am

In Monday's after-market session, several health care stocks experienced significant price movements. iRhythm Technologies (IRTC) saw a notable increase of 16.6%, while Sensei Biotherapeutics (SNSE) faced a sharp decline of 20.5%. Medpace Holdings (MEDP) also dropped by 12.17% following their Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 8:31 pm

Several healthcare stocks experienced significant intraday movements on Monday. Genprex, Inspire Veterinary, and BioVie saw substantial gains, while TC BioPharm, Meihua Intl Medical Techs, and Gritstone Bio faced notable declines.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.